Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME-CRT: Concurrent chemoradiotherapy ± induction chemo-immunotherapy followed by durvalumab in unresectable locally advanced NSCLC
jRCT1031260336Phase 3Recruiting
- Sponsor
- Japan Clinical Oncology Group
- Start
- Jul 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Japan Clinical Oncology Group. Primary endpoints: Progression-free survival and Overall survival. Started Jul 2026; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031260336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260336.